Skip to content

COVID19 Hospitilized in Clinica Pasteur of Neuquen (Argentina)

Cohort of COVID19 Patients Admitted to Pasteur Clinic 2020-2021

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05087394
Acronym
COVIDPas
Enrollment
1500
Registered
2021-10-21
Start date
2020-03-20
Completion date
2022-01-30
Last updated
2023-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

retrospective cohort (non-experimental study) of COVID 19 patients assisted in hospitalization (severe and critical) between 2020 and 2021

Detailed description

Consecutive patients with acute infection by SARS-COV2 and severe or critical COVID19 disease, or acute complications, hospitalized in the Pasteur Clinic of Neuquén city from the beginning of the pandemic in the region until December 31, 2021. Data were obtained retrospectively from information registered simultaneously with hospitalization in three databases (RedCap, DataTech and Excel). . Inclusion criteria * Adult patients (over 18 years old) * Suffering from acute infection by SARS-Cov2, diagnosed by PCR-real time, detection of viral antigen, specific antibodies with or clinical epidemiological criteria * Hospitalized defined by attending physicians or referral (severe or critical according to NIH) Exclusion criteria * Patients under 18 years of age. * Convalescent from acute SARS-Cov2 infection and without evidence of a new event of reinfection. * Outpatient management or hospitalization less than 24 hours for diagnosis and / or evaluation of severity or complications. Sample Selection Method First patient was registered at the beginning of the pandemic in the region March 20, 2020) and is expected to recruit the las patient diagnosed in December 31, 2021. The recruitment is consecutive without other selection criteria.

Interventions

OTHERComorbidities

Risk factors (comorbidities), requirements of respiratory suppot and chest imaging will are considered exposure for primary outcomes

Sponsors

Asociacion Latinoamericana de Torax
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adult patients (over 18 years old) * Suffering from acute infection by SARS-Cov2, diagnosed by PCR-real time, detection of viral antigen, specific antibodies with or clinical epidemiological criteria * Hospitalization defined by attending or referral physician (severe or critical according to NIH)

Exclusion criteria

* Patients under 18 years of age. * Convalescent from acute SARS-Cov2 infection and without evidence of a new event reinfection. * Outpatient management or hospitalization less than 24 hours for diagnosis and / or evaluation of severity or complications.

Design outcomes

Primary

MeasureTime frameDescription
28-day mortalityFrom date of admition until the date of death from any cause, assessed up to 28 daydefined as death ocurred within 28 days of admition to hospital
Hospital mortalityFrom date of admition until the date of death from any cause, assessed up to 52 weeksdefined as death ocurred within hospitalization

Secondary

MeasureTime frameDescription
Invasive Mechanical ventilationFrom date of admition until the date of equirement of invasive mechanical ventilation, assessed up to 21 daydefined as requirement of invasive mechanical ventilation support

Countries

Argentina

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026